Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/1058
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jong Bong Lee, Tae Hwan Kim | - |
dc.contributor.author | Wanshan Feng, Hyeon Gwan Choi | - |
dc.contributor.author | Atheer Zgair, Soyoung Shin | - |
dc.contributor.author | Sun Dong Yoo, Pavel Gershkovich | - |
dc.contributor.author | Beom Soo Shin | - |
dc.date.accessioned | 2022-10-15T08:33:17Z | - |
dc.date.available | 2022-10-15T08:33:17Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0022-3549 | - |
dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/1058 | - |
dc.description.abstract | For performance assessment of the lipid-based drug delivery systems (LBDDSs), in vitro lipolysis is commonly applied because traditional dissolution tests do not reflect the complicated in vivo micellar formation and solubilization processes. Much of previous research on in vitro lipolysis has mostly focused on rank-ordering formulations for their predicted performances. In this study, we have incorporated in vitro lipolysis with microsomal stability to quantitatively predict the oral bioavailability of a lipophilic antineoplastic drug bexarotene (BEX) administered in LBDDS. Two types of LBDDS were applied: lipid solution and lipid suspension. The predicted oral bioavailability values of BEX from linking in vitro lipolysis with microsomal stability for lipid solution and lipid suspension were 34.2 ± 1.6% and 36.2 ± 2.6%, respectively, whereas the in vivo oral bioavailability of BEX was tested as 31.5 ± 13.4% and 31.4 ± 5.2%, respectively. The predicted oral bioavailability corresponded well with the oral bioavailability for both formulations, demonstrating that the combination of in vitro lipolysis and microsomal stability can quantitatively predict oral bioavailability of BEX. In vivo intestinal lymphatic uptake was also assessed for the formulations and resulted in <1% of the dose, which confirmed that liver microsomal stability was necessary for correct prediction of the bioavailability | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Journal of Pharmaceutical Sciences | en_US |
dc.subject | lipid-based formulation | en_US |
dc.subject | absorption | en_US |
dc.subject | solubility | en_US |
dc.subject | bioavailability | en_US |
dc.subject | ymphatic transport | en_US |
dc.title | Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined In Vitro Lipolysis/Microsomal Metabolism Approach | en_US |
dc.type | Article | en_US |
Appears in Collections: | كلية الصيدلة |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Quantitative Prediction of Oral Bioavailability of a Lipophilic.pdf | 551.37 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.